Clinical trials: Metastatic Esophageal Cancer
Neuroendocrine Carcinoma
Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma
The study will be conducted to compare the safety and efficacy of irinotecan combined with cisplatin (IP regimen) and etoposide combined with cisplatin (EP regimen) in advanced or metastatic gastrointestinal pancreatic and…
- Trial name
- NCT03168594
- Testing
- irinotecan cisplatin, Etoposide cisplatin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University
Esophageal Cancer, Gastric Cancer
Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004127
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Gastrointestinal Cancer
Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
This is a phase 2, randomized, double blind, placebo controlled, multi-center study to estimate the improvement in progression free survival (compared to control subjects) and evaluate the safety and tolerability of AMG 386 in…
- Trial name
- NCT00583674
- Testing
- AMG 386 10mg/kg, AMG 386 3mg/kg, Cisplatin
- Volunteers
- 171 people
- Sponsor
- Amgen
Esophageal Cancer, Gastric Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00032123
- Testing
- erlotinib hydrochloride
- Where
- 107 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Esophageal Cancer
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or…
- Trial name
- NCT06769113
- Testing
- HLX43
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Shanghai Henlius Biotech
Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
The goal of this clinical trial is to evaluate the addition of ivonescimab to standard chemotherapy in patients with advanced or metastatic gastric and gastroesophageal adenocarcinoma.
- Conditions
- Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Advanced Gastric Adenocarcinoma
- Trial name
- GRACIE (NCT06846346)
- Testing
- Ivonescimab, FOLFOX regimen, Irinotecan
- Where
- 4 sites in France
- Volunteers
- 88 people
- Sponsor
- UNICANCER
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Metastatic Esophageal Squamous Cell Carcinoma
A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.
This study is a single-arm, prospective, phase II trial for patients with metastatic esophageal squamous cell carcinoma (ESCC) who received immunotherapy plus chemotherapy as the first-line treatment.
- Trial name
- NCT05760391
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Head Neck Cancer, Esophageal Cancer
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
This study wants to focus on Carcinoma detection rates with blue laser imaging (BLI) for participants with head-neck cancer who need a percutaneous endoscopic gastrostomy (PEG).
- Conditions
- Head Neck Cancer, Esophageal Cancer, Gastrostomy
- Trial name
- NCT04566367
- Testing
- blue laser imaging
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- Georg Dultz
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Metastatic Esophageal Cancer
Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced esophageal cancer.
- Trial name
- NCT02843581
- Testing
- Cryosurgery, NK immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
SHR-1210, Anlotinib
SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer
This study was designed to explore the clinical efficacy of SHR-1210 in combined with Anlotinib in the treatment of second- or above- line advanced or metastatic esophageal squamous cell cancer patients, in order to find a better…
- Conditions
- SHR-1210, Anlotinib, Advanced Esophageal Squamous Cell Cancer
- Trial name
- NCT04797507
- Testing
- SHR-1210 plus Anlotinib
- Volunteers
- 33 people
- Sponsor
- Peking Union Medical College Hospital
Gastric Neoplasms, Esophageal Cancer
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in patients with advanced abdominal cancer.
- Conditions
- Gastric Neoplasms, Esophageal Cancer, Liver Cancer, Liver Metastasis
- Trial name
- RIOT3 (NCT07001592)
- Testing
- vvDD-hIL-2-RG-1
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
The initial intent of the study was to be a multi-center single-arm open-label Simon's two-stage Phase II clinical trial of first-line mFOLFOX6 + trastuzumab + avelumab in metastatic HER2-amplified gastric and esophageal…
- Conditions
- Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis, HER-2 Gene Amplification
- Trial name
- NCT03783936
- Testing
- Oxaliplatin, Leucovorin, 5 fluorouracil
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ashwin Somasundaram
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Solid Tumors, Metastatic Melanoma
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04140500
- Testing
- RO7247669
- Where
- 25 sites in Denmark, Georgia and 7 more
- Volunteers
- 170 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer, Gastric Cancer
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00217581
- Testing
- Bevacizumab, Docetaxel, Oxaliplatin
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
HER2-expressing Cancers
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety…
- Trial name
- NCT03821233
- Testing
- ZW49
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 112 people
- Sponsor
- Zymeworks BC Inc.